Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway

Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel. However, synergy may not be fully exploited clinically because of distinct pharmacokin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Blanco, Elvin, Sangai, Takafumi, Wu, Suhong, Hsiao, Angela, Ruiz-Esparza, Guillermo U, Gonzalez-Delgado, Carlos A, Cara, Francisca E, Granados-Principal, Sergio, Evans, Kurt W, Akcakanat, Argun, Wang, Ying, Do, Kim-Anh, Meric-Bernstam, Funda, Ferrari, Mauro
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4088997/
https://ncbi.nlm.nih.gov/pubmed/24569835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2014.27
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados